Anemia Clinical Trial
Official title:
Impact Assessment of Benazir Nashonuma Program (BNP) on Stunting Prevention Among Children 0-59 Months of Age in Pakistan
The aim of the study is to evaluate the impact of Benazir Nashonuma Program (BNP) on prevalence of stunting among under-five children in low income setting of Pakistan. The research question that the study aims to answer is: Is there any change in the prevalence of stunting among under-five children in districts where Benazir Nashonuma Program (BNP) is established compared to districts where BNP is not established? Districts where BNP is functional, and women and children are receiving the intervention will be compared at baseline and end line with control districts where conventional reproductive care services are given. Prevalence of stunting among under-five children will be compared along with other nutritional and growth status indicators over a period of 4 years.
Status | Recruiting |
Enrollment | 13200 |
Est. completion date | June 30, 2026 |
Est. primary completion date | December 20, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Day to 59 Months |
Eligibility | All those households are eligible to be included in the study who have: - An under-five child with a mother registered with Benazir Income Support Program (BISP) - Both available at the time of interview Exclusion criteria includes: • Mother of the child who is not a woman of reproductive age, i.e., less than 15 years or greater than 49 years |
Country | Name | City | State |
---|---|---|---|
Pakistan | Aga Khan University | Karachi | Sindh |
Lead Sponsor | Collaborator |
---|---|
Aga Khan University | Bill and Melinda Gates Foundation, International Food Policy Research Institute |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline to end-line change in the prevalence of stunting among children 0-59 months of age | Height-for-age =-2 SD of the WHO Child growth standards median | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of underweight women of reproductive age (15-49 years) | WRA with a Body Mass Index (BMI) less than 18.5 kg/m2 will be considered underweight | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of wasting among children 0-59 months of age | Weight-for-height =-2 SD of the WHO Child growth standards median | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of food insecurity status at household level | Food Insecurity Experience Scale (FIES) by Food and Agriculture Organization (FAO) is experience-based measures of household or individual food security. It consists of eight questions regarding people's access to adequate food in last 12 months due to lack of money or other resources. Food insecurity is reported as mild, moderate and severe. | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the number of antenatal care (ANC) visits during pregnancy | Number of antenatal care (ANC) visits done during the preceding pregnancy, leading to a live birth within the last two years. | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of institutional deliveries | Number of women who gave birth at a healthcare facility during the preceding pregnancy, leading to a live birth within the last two years. | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of skilled birth attendance | Number of women whose birth was attended by a skilled health personnel during the preceding pregnancy, leading to a live birth within the last two years. | 3 years (on study completion) | |
Secondary | Baseline to end-line change in prevalence of utilization of iron folic acid (IFA) during pregnancy | Consumption of iron folic acid tablets during pregnancy | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of Minimum dietary diversity for women (MDDW) | Consumption of at least five out of the ten food groups during the previous day and night (24 hours) | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of infants who were ever breastfed | Number of infants who were breastfed at least once | 3 years (on study completion) | |
Secondary | Baseline to end-line change in the prevalence of exclusive breastfeeding among infants 0-5 months of age | Number of infants who were fed exclusively with breast milk during the previous day | 3 years (on study completion) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |